検索結果

研究開発の取り組み | 千寿製薬株式会社

R & D activities Product Development Policy Research and Development System R & D Pipeline Clinical trial information Publications Meetings of the Minds Business Collaboration Inquiries licens...

アバレプト懸濁性点眼液0.3％に関するよくあるご質問 | 医療関係者向製品情報（医療用医薬品） | 医療関係者のみなさま | 千寿製薬株式会社

2％) 0 0 (MedDRA/J version 23.1) a) MedDRA（国際医薬用語集；Medical Dictionary for Regulatory Activities）のSOC（System Organ Class）及びPT（基本語；Preferred term） b) MedDRAのLLT（下層語；Lowest Level Term）の眼部熱感を含む ＜第Ⅲ相比較試験 3-...

Quality Policies | About Senju | SENJU Pharmaceutical

as medical consumers and/or providers. · We conduct risk management to continuously improve quality systems for pharmaceuticals and other products （Management Resources） · We allocate appropriate mana...

千寿製薬について | 千寿製薬株式会社

ent Policy Company Profile Our Initiatives for Society / Environment Business Activities Production system Quality policy

tial cation channel subfamily V member 1 (TRPV1) *1 antagonist, designed to improve both subjective symptoms and objective signs of DED through inhibition of TRPV1. A pivotal Phase III clinical trial ...